Rituximab Therapy and Its Effects on T Cell Responses in Autoimmune Encephalomyelitis
Author Information
Author(s): Monson Nancy L., Cravens Petra, Hussain Rehana, Harp Christopher T., Cummings Matthew, de Pilar Martin Maria, Ben Li-Hong, Do Julie, Lyons Jeri-Anne, Lovette-Racke Amy, Cross Anne H., Racke Michael K., Stüve Olaf, Shlomchik Mark, Eagar Todd N.
Primary Institution: University of Texas Southwestern Medical Center
Hypothesis
What is the impact of Rituximab on T cell responses in experimental autoimmune encephalomyelitis (EAE)?
Conclusion
Rituximab treatment reduces the severity of EAE by depleting B cells and altering T cell responses.
Supporting Evidence
- Rituximab administration rapidly depleted peripheral B cells.
- B cell depletion was associated with diminished T cell proliferation.
- EAE severity was significantly reduced in mice treated with Rituximab.
- Rituximab treatment altered T cell responses in the spleen and CNS.
Takeaway
Rituximab helps treat a disease by removing certain immune cells, which makes the disease less severe.
Methodology
The study used a mouse model of EAE to assess the effects of Rituximab on B and T cell responses.
Limitations
The study was conducted in a mouse model, which may not fully replicate human disease.
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website